Counter-regulation of alpha- and beta-synuclein expression at the transcriptional level

Mol Cell Neurosci. 2013 Nov:57:33-41. doi: 10.1016/j.mcn.2013.09.002. Epub 2013 Sep 27.

Abstract

Alpha-synuclein is a cytosolic protein associated with a range of diseases including Parkinson's disease. In these diseases alpha-synuclein aggregates and this is believed to play a causative role in disease progression. Alpha-synuclein aggregation has been suggested to be caused by increased expression levels and has also been suggested to be countered by increased beta-synuclein expression. In this regard, strategies to counter-regulate the expression of the synucleins by increasing beta-synuclein expression relative to alpha-synuclein may be beneficial in preventing disease progression. We therefore studied the regulation of alpha-synuclein to try to identify pathways that might counter-regulate the synucleins. We identified members of the ZSCAN family of transcription factors as specific repressors of alpha-synuclein. In particular ZSCAN21 was found to both repress alpha-synuclein and increase beta-synuclein expression. These findings support the notion that a single pathway in the cell can counter-regulate the expression of the synucleins. Support for this came from experiments that showed that ZSCAN21 expression decreases alpha-synuclein aggregation in the cells.

Keywords: NRF2; Parkinson's disease; Synuclein; Transcription factors; ZSCAN.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Humans
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Transcription Factors / genetics
  • Transcription Factors / metabolism
  • Transcriptional Activation*
  • alpha-Synuclein / genetics
  • alpha-Synuclein / metabolism*
  • beta-Synuclein / genetics
  • beta-Synuclein / metabolism*

Substances

  • RNA, Messenger
  • Transcription Factors
  • alpha-Synuclein
  • beta-Synuclein